A Randomized, Double-Blind, Placebo-Controlled Trial of Porcine Versus Synthetic Secretin for Reducing Symptoms of Autism

Alan S. Unis, Jeffrey A. Munson, Sally J Rogers, Ed Goldson, Julie Osterling, Robin Gabriels, Robert D. Abbott, Geraldine Dawson

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: To compare the effects of a single dose of biologic and synthetic porcine secretin to placebo on a variety of autism symptoms. Method: Eighty-five children with autism without other medical conditions and not taking other psychotropic medications participated (ages between 3 and 12 years, mean IQ = 55). Children were grouped into trios matched by age and communication level and then randomly assigned to one of three treatment groups: biologic secretin (2 CU/kg), synthetic secretin (0.4 μg/kg), and placebo. Measures collected 1 week before and 4 weeks after infusion included autism symptoms, language skills, and problem behaviors, gathered from parents, teachers, and investigators, who were all blind to treatment. Two-factor, repeated-measures analyses of variance (3 treatment levels by 2 repeated measures, pre- and postinfusion) were used to examine efficacy. Results: Direct observation measures did not show change over time related to secretin. Parent reports showed an overall reduction of symptom severity for all treatment groups, including the placebo group. One teacher-report measure showed decreases in autism symptoms in the placebo and synthetic secretin groups. Conclusions: No evidence that either biologic or synthetic secretin provided amelioration of symptoms beyond placebo was observed. This held true when children with and without gastrointestinal problems were examined separately.

Original languageEnglish (US)
Pages (from-to)1315-1321
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume41
Issue number11
DOIs
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Secretin
Autistic Disorder
Swine
Placebos
Therapeutics
Analysis of Variance
Language
Parents
Communication
Research Personnel
Observation

Keywords

  • Autism
  • Psychopharmacology
  • Secretin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

A Randomized, Double-Blind, Placebo-Controlled Trial of Porcine Versus Synthetic Secretin for Reducing Symptoms of Autism. / Unis, Alan S.; Munson, Jeffrey A.; Rogers, Sally J; Goldson, Ed; Osterling, Julie; Gabriels, Robin; Abbott, Robert D.; Dawson, Geraldine.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 41, No. 11, 11.2002, p. 1315-1321.

Research output: Contribution to journalArticle

Unis, Alan S. ; Munson, Jeffrey A. ; Rogers, Sally J ; Goldson, Ed ; Osterling, Julie ; Gabriels, Robin ; Abbott, Robert D. ; Dawson, Geraldine. / A Randomized, Double-Blind, Placebo-Controlled Trial of Porcine Versus Synthetic Secretin for Reducing Symptoms of Autism. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2002 ; Vol. 41, No. 11. pp. 1315-1321.
@article{c7b7b7b8b5fb4623bdfaee5619aa186e,
title = "A Randomized, Double-Blind, Placebo-Controlled Trial of Porcine Versus Synthetic Secretin for Reducing Symptoms of Autism",
abstract = "Objective: To compare the effects of a single dose of biologic and synthetic porcine secretin to placebo on a variety of autism symptoms. Method: Eighty-five children with autism without other medical conditions and not taking other psychotropic medications participated (ages between 3 and 12 years, mean IQ = 55). Children were grouped into trios matched by age and communication level and then randomly assigned to one of three treatment groups: biologic secretin (2 CU/kg), synthetic secretin (0.4 μg/kg), and placebo. Measures collected 1 week before and 4 weeks after infusion included autism symptoms, language skills, and problem behaviors, gathered from parents, teachers, and investigators, who were all blind to treatment. Two-factor, repeated-measures analyses of variance (3 treatment levels by 2 repeated measures, pre- and postinfusion) were used to examine efficacy. Results: Direct observation measures did not show change over time related to secretin. Parent reports showed an overall reduction of symptom severity for all treatment groups, including the placebo group. One teacher-report measure showed decreases in autism symptoms in the placebo and synthetic secretin groups. Conclusions: No evidence that either biologic or synthetic secretin provided amelioration of symptoms beyond placebo was observed. This held true when children with and without gastrointestinal problems were examined separately.",
keywords = "Autism, Psychopharmacology, Secretin",
author = "Unis, {Alan S.} and Munson, {Jeffrey A.} and Rogers, {Sally J} and Ed Goldson and Julie Osterling and Robin Gabriels and Abbott, {Robert D.} and Geraldine Dawson",
year = "2002",
month = "11",
doi = "10.1097/00004583-200211000-00012",
language = "English (US)",
volume = "41",
pages = "1315--1321",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - A Randomized, Double-Blind, Placebo-Controlled Trial of Porcine Versus Synthetic Secretin for Reducing Symptoms of Autism

AU - Unis, Alan S.

AU - Munson, Jeffrey A.

AU - Rogers, Sally J

AU - Goldson, Ed

AU - Osterling, Julie

AU - Gabriels, Robin

AU - Abbott, Robert D.

AU - Dawson, Geraldine

PY - 2002/11

Y1 - 2002/11

N2 - Objective: To compare the effects of a single dose of biologic and synthetic porcine secretin to placebo on a variety of autism symptoms. Method: Eighty-five children with autism without other medical conditions and not taking other psychotropic medications participated (ages between 3 and 12 years, mean IQ = 55). Children were grouped into trios matched by age and communication level and then randomly assigned to one of three treatment groups: biologic secretin (2 CU/kg), synthetic secretin (0.4 μg/kg), and placebo. Measures collected 1 week before and 4 weeks after infusion included autism symptoms, language skills, and problem behaviors, gathered from parents, teachers, and investigators, who were all blind to treatment. Two-factor, repeated-measures analyses of variance (3 treatment levels by 2 repeated measures, pre- and postinfusion) were used to examine efficacy. Results: Direct observation measures did not show change over time related to secretin. Parent reports showed an overall reduction of symptom severity for all treatment groups, including the placebo group. One teacher-report measure showed decreases in autism symptoms in the placebo and synthetic secretin groups. Conclusions: No evidence that either biologic or synthetic secretin provided amelioration of symptoms beyond placebo was observed. This held true when children with and without gastrointestinal problems were examined separately.

AB - Objective: To compare the effects of a single dose of biologic and synthetic porcine secretin to placebo on a variety of autism symptoms. Method: Eighty-five children with autism without other medical conditions and not taking other psychotropic medications participated (ages between 3 and 12 years, mean IQ = 55). Children were grouped into trios matched by age and communication level and then randomly assigned to one of three treatment groups: biologic secretin (2 CU/kg), synthetic secretin (0.4 μg/kg), and placebo. Measures collected 1 week before and 4 weeks after infusion included autism symptoms, language skills, and problem behaviors, gathered from parents, teachers, and investigators, who were all blind to treatment. Two-factor, repeated-measures analyses of variance (3 treatment levels by 2 repeated measures, pre- and postinfusion) were used to examine efficacy. Results: Direct observation measures did not show change over time related to secretin. Parent reports showed an overall reduction of symptom severity for all treatment groups, including the placebo group. One teacher-report measure showed decreases in autism symptoms in the placebo and synthetic secretin groups. Conclusions: No evidence that either biologic or synthetic secretin provided amelioration of symptoms beyond placebo was observed. This held true when children with and without gastrointestinal problems were examined separately.

KW - Autism

KW - Psychopharmacology

KW - Secretin

UR - http://www.scopus.com/inward/record.url?scp=0036831724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036831724&partnerID=8YFLogxK

U2 - 10.1097/00004583-200211000-00012

DO - 10.1097/00004583-200211000-00012

M3 - Article

C2 - 12410073

AN - SCOPUS:0036831724

VL - 41

SP - 1315

EP - 1321

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 11

ER -